74. Prolactin secreting pituitary adenoma
[
15 clinical trials,
25 drugs（DrugBank:
10 drugs),
16 target genes / 62 target pathways ]
Searched query = "Prolactin secreting pituitary adenoma", "Pituitary PRL secretion hyperthyroidism", "Prolactinoma", "Prolactin secreting adenoma"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04107480 | June 21, 2019 | 14 October 2019 | PRolaCT - Three Prolactinoma RCTs | PRolaCT - Three Multicenter Prolactinoma Randomized Clinical Trials | Prolactinoma;Prolactin-Producing Pituitary Tumor | Procedure: Endoscopic trans-sphenoidal adenoma resection;Drug: Dopamine Agonists | Leiden University Medical Center | Recruiting | 18 Years | N/A | All | 660 | Phase 4 | Netherlands | |
| 2 | NCT03717454 | December 1, 2018 | 3 December 2018 | Dopamine D2 Receptors(D2R) Imaging in Prolactinomas | The Predictive Value of Positron Emission Tomography-Magnetic Resonance (PET-MR) Mediated Dopamine D2 Receptors Imaging in the Drug Therapy of of Prolactinomas. | Prolactinoma | Other: Surgery;Drug: Drug treatment | Zhebao Wu | Xinqiao Hospital of Chongqing;First Hospital of China Medical University;Beijing Tiantan Hospital;First Affiliated Hospital of Wenzhou Medical University;First Affiliated Hospital of Fujian Medical University;Peking Union Medical College Hospital;Huashan Hospital;Chinese PLA General Hospital | Not recruiting | 18 Years | 65 Years | All | 50 | N/A | |
| 3 | NCT03457389 | October 1, 2018 | 1 October 2018 | Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma | Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma: A Prospective, Randomized, Open Label, Active-controlled, Clinical Trial | Pituitary Adenoma;Prolactinoma;Pituitary Tumor;Recurrence Tumor | Drug: Cabergoline | Seoul National University Hospital | Not recruiting | 19 Years | N/A | All | 68 | N/A | Korea, Republic of | |
| 4 | NCT03038308 | September 16, 2016 | 16 September 2019 | Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole | Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole: A Dose Escalation Study of Efficacy and Tolerability | Hyperprolactinemia;Prolactinoma | Drug: Ropinirole | Columbia University | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Recruiting | 18 Years | 70 Years | All | 26 | Phase 1/Phase 2 | United States |
| 5 | NCT03353025 | January 1, 2016 | 16 December 2017 | Study on Therapy of Non-invasive Prolactinoma | Prospective Randomized Clinical Study on Transsphenoidal or Dopamine Drugs Therapy Treat Non-invasive Prolactinoma | Prolactinoma | Procedure: transsphenoidal surgery treatment;Drug: dopamine agonist treatment | First Affiliated Hospital, Sun Yat-Sen University | Recruiting | 18 Years | 60 Years | All | 394 | N/A | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | ChiCTR-ONC-12002194 | 2012-05-01 | 18 April 2017 | Artery Endothelium Function, Carotid Artery Intima-Media Thickness and Cardiac Mass and Function after Long-Term Control of Hyperprolactimia | Artery Endothelium Function, Carotid Artery Intima-Media Thickness and Cardiac Mass and Function after Long-Term Control of Hyperprolactimia | prolactinoma | patients with prolactinoma:treatment with bromocriptine ; | First affiliated hospital of Sun Yat-sen University | Not Recruiting | 13 | 55 | Both | patients with prolactinoma:40; | Other | ||
| 7 | NCT01344291 | July 2011 | 19 February 2015 | Turmeric Effect on Reduction of Serum Prolactin and Related Hormonal Change and Adenoma Size in Prolactinoma Patients | Hyperprolactinoma | Drug: Curcumin | Mashhad University of Medical Sciences | Recruiting | 20 Years | 45 Years | Female | 30 | Phase 1 | Iran, Islamic Republic of | ||
| 8 | NCT01088763 | March 2010 | 19 February 2015 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia | A PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIA | Childhood Atypical Teratoid/Rhabdoid Tumor;Childhood Central Nervous System Choriocarcinoma;Childhood Central Nervous System Germinoma;Childhood Central Nervous System Mixed Germ Cell Tumor;Childhood Central Nervous System Teratoma;Childhood Central Nervous System Yolk Sac Tumor;Childhood Choroid Plexus Tumor;Childhood Craniopharyngioma;Childhood Ependymoblastoma;Childhood Grade I Meningioma;Childhood Grade II Meningioma;Childhood Grade III Meningioma;Childhood Infratentorial Ependymoma;Childhood Medulloepithelioma;Childhood Mixed Glioma;Childhood Oligodendroglioma;Childhood Supratentorial Ependymoma;Gonadotroph Adenoma;Pituitary Basophilic Adenoma;Pituitary Chromophobe Adenoma;Pituitary Eosinophilic Adenoma;Prolactin Secreting Adenoma;Recurrent Childhood Acute Lymphoblastic Leukemia;Recurrent Childhood Anaplastic Large Cell Lymphoma;Recurrent Childhood Brain Stem Glioma;Recurrent Childhood Central Nervous System Embryonal Tumor;Recurrent Childhood Cerebellar Astrocytoma;Recurrent Childhood Cerebral Astrocytoma;Recurrent Childhood Ependymoma;Recurrent Childhood Grade III Lymphomatoid Granulomatosis;Recurrent Childhood Large Cell Lymphoma;Recurrent Childhood Lymphoblastic Lymphoma;Recurrent Childhood Medulloblastoma;Recurrent Childhood Pineoblastoma;Recurrent Childhood Small Noncleaved Cell Lymphoma;Recurrent Childhood Spinal Cord Neoplasm;Recurrent Childhood Subependymal Giant Cell Astrocytoma;Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;Recurrent Childhood Visual Pathway and Hypothalamic Glioma;Recurrent Childhood Visual Pathway Glioma;Recurrent Pituitary Tumor;Recurrent/Refractory Childhood Hodgkin Lymphoma;T-cell Childhood Acute Lymphoblastic Leukemia;T-cell Large Granular Lymphocyte Leukemia;TSH Secreting Adenoma;Unspecified Childhood Solid Tumor, Protocol Specific | Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;Other: diagnostic laboratory biomarker analysis;Other: pharmacological study;Drug: dexamethasone | National Cancer Institute (NCI) | Not recruiting | 1 Year | 21 Years | Both | 129 | Phase 1 | United States;Canada | |
| 9 | NCT01620138 | March 2010 | 19 October 2017 | Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas | Somatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine Agonist | Non-functioning Pituitary Adenomas;Prolactinomas | Drug: Pasireotide;Drug: cabergoline | Universidade Federal do Rio de Janeiro | Not recruiting | 18 Years | N/A | All | 21 | Phase 2/Phase 3 | Brazil | |
| 10 | EUCTR2009-010918-30-IE | 11/08/2009 | 19 March 2012 | Effect of growth hormone replacement on cortisol-to-cortisone interconversion in hypopituitary patients with growth hormone deficiency and the influence of different aetiologies of hypopituitarism. | Effect of growth hormone replacement on cortisol-to-cortisone interconversion in hypopituitary patients with growth hormone deficiency and the influence of different aetiologies of hypopituitarism. | 20 patients with hypopituitarism including growth hormone deficiency will be evaluated both on growth hormone replacement and when they have been off it for a 2 month period. They will have been prescribed growth hormone replacement in the form of Genotropin/Genotropin Miniquick/Norditropin prior to inclusion in this study as part of their routine clinical care. MedDRA version: 9.1 Level: LLT Classification code 10021067 Term: Hypopituitarism MedDRA version: 9.1 Level: LLT Classification code 10033662 Term: Panhypopituitarism MedDRA version: 9.1 Level: LLT Classification code 10056438 Term: Growth hormone deficiency MedDRA version: 9.1 Level: LLT Classification code 10011318 Term: Craniopharyngioma MedDRA version: 9.1 Level: LLT Classification code 10036832 Term: Prolactinoma MedDRA version: 9.1 Level: LLT Classification code 10011651 Term: Cushing's disease MedDRA version: 9.1 Level: LLT Classification code 10035104 Term: Pituitary tumour MedDRA version: 9.1 Level: LLT Classification code 10061538 Term: Pituitary tumour benign | Trade Name: Genotropin 5.3mg Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: SOMATROPIN CAS Number: 12629015 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 5.3- Trade Name: Genotropin 12mg Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: SOMATROPIN CAS Number: 12629015 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 12- Trade Name: Genotropin Miniquick 0.2mg Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: SOMATROPIN CAS Number: 12629015 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.2- Trade Name: Genotropin Miniquick 0.4mg Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: SOMATROPIN CAS Number: 12629015 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.4- Trade Name: Genotropin Miniquick 0.6mg Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: SOMATROPIN CAS Number: 12629015 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.6- Trade Name: Genotropin Miniquick 0.8mg Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: SOMATROPIN CAS Number: 12629015 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.8- Trade Name: Genotropin Miniquick 1.0mg Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: SOMATROPIN CAS Number: 12629015 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.0- Trade Name: Genotropin Miniquick 1.2mg Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: SOMATROPIN CAS Number: 12629015 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.2- | Amar Agha, Beaumont Hospital | Authorised | Female: yes Male: yes | 20 | Ireland | ||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT00939523 | July 2009 | 11 February 2019 | Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy | Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy | Pituitary Adenomas;Prolactinomas | Drug: Lapatinib | Cedars-Sinai Medical Center | Not recruiting | 18 Years | N/A | All | 12 | Phase 2 | United States | |
| 12 | EUCTR2008-007348-32-FR | 06/05/2009 | 22 August 2016 | An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - NA | An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - NA | The following tumors are included: 1. NETs of the pancreas or duodenum: Insulinoma, Gastrinoma, VIPoma, glucagonoma, 2. Pituitary NETs: Thyrotropic-pituitary adenoma (TSH), Gonadotropic adenoma, Prolactinoma (PRL) and non-functioning pituitary adenoma (NFPA) 3. Ectopic ACTH-secreting (EAS) tumors 4. Nelson’s syndrome MedDRA version: 9.1 Level: LLT Classification code 10062476 Term: Neuroendocrine tumor | Product Name: pasireotide Product Code: SOM230 Pharmaceutical Form: Powder and solvent for suspension for injection INN or Proposed INN: Pasireotide Current Sponsor code: SOM230 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Product Name: pasireotide Product Code: SOM230 Pharmaceutical Form: Powder and solvent for suspension for injection INN or Proposed INN: Pasireotide Current Sponsor code: SOM230 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Product Name: pasireotide Product Code: SOM230 Pharmaceutical Form: Solution for injection INN or Proposed INN: Pasireotide Current Sponsor code: SOM230 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 600- | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 100 | Phase 2 | France;Spain;Germany;Italy | |||
| 13 | EUCTR2006-007036-95-DE | 02/07/2008 | 19 March 2012 | Monocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Prolactinomas - proof of concept study | Monocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Prolactinomas - proof of concept study | Prolactinoma MedDRA version: 9.1 Level: LLT Classification code 10036832 Term: Prolactinoma | Product Code: SOM230 Pharmaceutical Form: Injection* INN or Proposed INN: Pasireotide Current Sponsor code: SOM230 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 600- Product Code: SOM230 Pharmaceutical Form: Injection* INN or Proposed INN: Pasireotide Current Sponsor code: SOM230 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 900- | Universitätsklinikum Essen - Zentrum für Innere Medizin - Klinik für Endokrinologie | Not Recruiting | Female: yes Male: yes | Germany | |||||
| 14 | NCT00460616 | January 2007 | 19 February 2015 | Cardiac Valve Complications in Prolactinomas Treated With Cabergoline | Observational Study to Investigate the Prevalence of Cardiac Abnormalities and Valvular Regurgitation in Patients With Prolactinomas Treated Chronically With Cabergoline | Prolactinomas | Drug: Cabergoline | Federico II University | Not recruiting | 18 Years | 65 Years | Both | 50 | Phase 4 | Italy | |
| 15 | NCT00697814 | June 2004 | 19 February 2015 | Clomiphene in Males With Prolactinomas and Persistent Hypogonadism | Recovery of Gonadal Function by Clomiphene in Males With Prolactinomas and Persistent Hypogonadism | Hypogonadotropic Hypogonadism;Prolactinoma | Drug: Clomiphene citrate | Federal University of São Paulo | Not recruiting | 18 Years | 70 Years | Male | 15 | Phase 2 | Brazil |